INOTREM
Inotrem S.A., a biotechnology company specialized in the control of acute inflammatory syndromes such as septic shock, has appointed Martin Koch as Chief Operating Officer (COO).
Martin Koch comes to Inotrem with more than 25 years of experience in the healthcare industry. Prior to joining Inotrem, Martin spent 10 years at Genticel, a biotechnology company developing innovative immunotherapies. As Genticel’s Chief Financial Officer, Martin was instrumental to the successful growth of the company from the first institutional financing round (2008) to the 2014 IPO on Euronext Paris and Brussels, followed by the merger with GenKyoTex in 2017. Martin Koch brings also to Inotrem a strong international background, having worked in France, Eastern Europe and the UK for top tier companies such as Eli Lilly, Elan Pharmaceuticals and Cephalon.
At Inotrem, Martin will be responsible for supervising the financial activities and secure the business plan’s delivery. As part of Inotrem’s executive management team, he will actively contribute to the company’s strategic development.
Martin Koch, COO, says: « I am thrilled to join such a talented team as the one Jean-Jacques Garaud brought together, and participate to Inotrem’s promising project. It is a wonderful opportunity to contribute to the development of MOTREM TM , the first drug candidate which has the potential to directly act on the immunological mechanism leading to septic shock. With high mortality rates, ranging from 25% to 40%, septic shock is considered by the World Health Organization to be a public health priority ».
Jean-Jacques Garaud, Inotrem’s President, adds: « We are extremely pleased to welcome Martin as COO. His operational expertise and international background perfectly fit our team. With him on board, Inotrem is ideally positioned to seize growth opportunities, at a pivotal time when the firm’s lead compound MOTREM TM is close to complete its first clinical trial in septic shock patients ».
About Inotrem
Inotrem is a biotechnology company specialized in the control of excessive immune response that occurs in acute inflammatory syndromes in the critical care setting. It has developed a new concept of immunomodulation to control abnormal immune response to tissue injuries, using a personalized medicine approach. The Company has been founded in 2013 in Nancy by Dr. Jean-Jacques Garaud, a former head of research and early development at the Roche Group, Prof. Sébastien Gibot and Dr. Marc Derive.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180117006353/en/
Contact:
Press for Inotrem
S&I
Anne REIN, +33 6 03 35 92 05
anne.rein@strategiesimage.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-NETAPP18.3.2024 23:01:28 CET | Press release
NetApp Empowers Customers to Securely “Talk to Their Data” in Collaboration with NVIDIA
KPMG18.3.2024 18:39:35 CET | Press release
KPMG’s "Digital Gateway for Tax" Platform Raises Global Standards in Tax Functionality with Generative AI
DANCHURCHAID18.3.2024 18:07:34 CET | Press release
Media invitation: World leaders must make headway for adaptation - there are no alternatives
CA-VERIMATRIX18.3.2024 17:46:33 CET | Press release
Verimatrix Releases Counterspy as a New Anti-Piracy Solution with First-Ever Defensive Capabilities
VERACODE18.3.2024 15:43:32 CET | Press release
Centrico Spa (Gruppo Banca Sella) and Veracode Enter Deal to Help Secure the Application Development Life Cycle
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom